Drug Profile
Research programme: therapeutics - Newron
Latest Information Update: 18 Aug 2020
Price :
$50
*
At a glance
- Originator Newron Pharmaceuticals
- Class Neuroprotectants
- Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research CNS disorders; Peripheral nervous system diseases
- No development reported Neuropathic pain; Pain
Most Recent Events
- 11 Aug 2020 Therapeutics - Newron is available for licensing as of 11 Aug 2020. https://www.newron.com/
- 11 Aug 2020 Early research in CNS disorders in Italy
- 11 Aug 2020 Early research in Peripheral nervous system diseases in Italy